David R. Spigel, Chief Scientific Officer at Sarah Cannon Research Institute, shared a post on LinkedIn:
“It’s hard to believe ASCO was already a month ago. As we move into the second half of the year, it’s worth reflecting on the key themes and insights that emerged from the meeting – and the areas that continue to command our attention as we work to advance cancer care and research.
This year’s meeting highlighted important advances across multiple disease areas, from pancreatic cancer and precision medicine to blood cancers and immunotherapy. Each breakthrough reflects years of dedication from investigators, research teams, industry partners and, most importantly, the patients who make clinical research possible.
I’m proud of the contributions from more than 85 Sarah Cannon Research Institute first authors and coauthors representing 30+ research sites. The progress we celebrated this year gives me even greater optimism for what comes next.
From Discovery to Impact: Reflections from ASCO 2026
Every year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together the global oncology community to share advancements and drive progress in cancer care. This year’s theme, The Science and Practice of Translation: Improving Cancer Outcomes Worldwide, reflected a central idea that resonated throughout the meeting: scientific breakthroughs only reach their full potential when they can be translated into meaningful improvements for patients.
Across disease areas, ASCO 2026 showcased important progress in precision medicine, immunotherapy and novel clinical trial approaches. I left the meeting encouraged by the pace of innovation and grateful to the patients who participate in clinical research, making every breakthrough possible.
A New Chapter for Pancreatic Cancer
Perhaps the biggest story from this year’s meeting was about the progress in pancreatic cancer research. Data presented from the Phase 3 RASolute 302 study evaluating daraxonrasib in previously treated metastatic pancreatic cancer demonstrated a doubling of median overall survival and progression-free survival compared with standard chemotherapy, with improvements in objective response rates and patient-reported outcomes. For a disease that has historically seen limited therapeutic advances, these findings represent an important step forward.
At SCRI, we’ve had the privilege of participating in this research and caring for patients enrolled in the study. Watching patients regain strength, return to everyday activities and spend more meaningful time with their families is a powerful reminder that this research represents real people whose lives have been changed through new therapies.
Just as importantly, this breakthrough creates momentum. It provides a foundation for future combinations, earlier intervention strategies, and continued innovation that could reshape the treatment landscape for pancreatic cancer in the years ahead.
Precision Medicine Continues to Expand
Another clear theme across ASCO 2026 was the continued evolution of precision oncology, with targeted therapies moving into earlier lines of treatment and demonstrating meaningful improvements across multiple tumor types.
Melissa Johnson, Chief Scientific Officer and Director of Lung Cancer Research at SCRI, served as a coauthor on the Phase 3 LIBRETTO-432 trial, presented during the Plenary Session, which demonstrated significant improvement in event-free survival with adjuvant selpercatinib for patients with stage IB-IIIA RET fusion-positive non-small cell lung cancer. Beyond informing a potential new standard of care, the study reinforces the growing importance of comprehensive biomarker testing and raises an important conversation around expanding access to lung cancer screening for patients who may not fit traditional risk profiles.
In breast cancer, the Phase 3 VIKTORIA-1 study highlighted the promise of multi-target pathway inhibition for patients with PIK3CA-mutated disease, demonstrating improved progression-free survival compared with current standard approaches and reinforcing how a deeper understanding of tumor biology continues to translate into better treatment options.
We also saw encouraging progress across blood cancers. John Burke, Member, Lymphoma Research Executive Committee, SCRI at Rocky Mountain Cancer Centers, coauthored the Phase 3 frontMIND study, which demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival, representing one of the first studies in years to meaningfully improve upon this longstanding standard of care.
Additional presentations reflected continued momentum across hematologic malignancies. Hans Lee, Director, Myeloma Research, SCRI, presented encouraging early data from the LINKER-AL2 trial evaluating linvoseltamabinrelapsed AL amyloidosis, demonstrating rapid and deep responses in an area with significant unmet need and no approved therapies. Peter Forsberg, Member, Myeloma Research Executive Committee, SCRI at Colorado Blood Cancer Institute, delivered findings from the OPTec/OPTal trial showing that a single preventive dose of tocilizumab reduced the risk of cytokine release syndrome without compromising safety or efficacy, an approach that could help expand outpatient delivery of these important therapies.
These studies highlight an exciting trend across oncology: increasingly personalized, collaborative and patient-centered research is creating new opportunities to improve outcomes across disease stages and tumor types.
Innovation Across Immunotherapy
Immunotherapy remains a dominant pillar of cancer research, and this year’s meeting demonstrated that innovation continues well beyond the checkpoint inhibitors that transformed oncology over the last decade.
Novel bispecific antibodies, targeted combinations and first-in-class therapies generated compelling data across uveal melanoma as well as lung, head and neck and ovarian cancers.
Among the notable presentations was the Phase 3 HARMONi-6 study evaluating ivonescimab plus chemotherapy in advanced non-small cell lung cancer, which demonstrated significant improvements in overall survival and generated considerable excitement around the future of PD-1/VEGF bispecific therapies.
We also saw encouraging progress in uveal melanoma, where the OptimUM-02 trial evaluating darovasertib plus crizotinib demonstrated clinically meaningful improvements in progression-free survival and response rates. Meredith McKean, Director, Melanoma and Skin Cancer Research; SCRI, served as a coauthor on the study, which represents an important step forward for patients with a disease that has historically had limited treatment options.
The Takeaway: Advancing Research Together
While it’s impossible to capture every important story from ASCO 2026 in a single article, what continues to stand out is the collective strength of the Sarah Cannon Research Institute network.
Across more than 155 accepted abstracts and presentations, our investigators and research teams contributed to practice-changing science spanning solid tumors, hematologic malignancies, immunotherapy and precision oncology. Those contributions reflect not only scientific excellence, but the power of a collaborative research model that brings together community oncology practices, academic partners and industry sponsors with a shared commitment to advancing patient care.
I’m especially proud to bring this mission to life through SCRI Oncology Partners, supported by the deep scientific expertise of SCRI and strengthened by our collaboration with The US Oncology Network. Together, we are expanding access to innovative clinical trials and helping ensure that promising discoveries reach patients faster and closer to home.
The discoveries presented this year will shape tomorrow’s standards of care, and I look forward to continuing that work together.”
Other articles about Pancreatic Cancer on OncoDaily.